When a fallen giant stops falling, the market usually waits for a full recovery before it pays up again.

Stick with us, and you’ll see the receipts this one just printed, and why you can still pick them up at a discount.

Built for business. Ready for anything.

With built-in intelligence, you can stay productive and focused on growing your small business. So no matter what the day throws at you, your Dell Pro can handle it.

Explore More

Materials

Avient Corporation (NYSE: AVNT) raised its annual adjusted earnings outlook after third-quarter revenue increased 10.5% to $891.2 million. Adjusted EPS rose 23% to $0.86, while organic sales expanded 10.6% and adjusted EBITDA climbed 16% to $154.4 million.

At approximately $48.27, Avient carried a $4.43 billion market value and traded around 14.8 times the midpoint of its revised $3.22 to $3.32 adjusted EPS forecast. Its $5.81 billion enterprise value represented roughly 9.7 times projected annual adjusted EBITDA, reflecting a reasonable, though not exceptionally low, valuation.

Specialty Engineered Materials sales jumped 14.4% to $340.6 million, outpacing 8.2% growth in Color, Additives and Inks. Ignoring that difference would lead you to value faster-growing specialty materials like ordinary cyclical products, despite their stronger operating momentum.

Specialty Demand Supports Higher Margins

Adjusted EBITDA margin reached 17.3%, up 80 basis points, supported by stronger pricing and product mix.

Nine-month operating cash flow increased to $180 million from $133.8 million, while free cash flow rose approximately 63% to $113.6 million. Avient also repaid $100 million in debt during the first nine months and expects year-end net leverage of 2.2 to 2.3 times EBITDA.

The Rally Narrows the Valuation Cushion

Shares gained more than 11% following the results, while total debt remained near $1.83 billion. Cash generation remains modest relative to market value, and weaker industrial demand could pressure volumes and margins.

Sustained specialty orders must support your earnings expectations now that the share price already reflects considerable optimism.

Payments

CPI Card Group (NASDAQ: PMTS) reported third-quarter revenue of $158.4 million, up 14.8%, while net income more than doubled to $5 million. Gross profit increased 22.6% to $50.3 million, and management raised its annual free cash flow forecast for the second consecutive quarter.

At approximately $26.82 per share, CPI traded near $312 million against expected 2026 free cash flow of $50 million to $55 million. The $52.5 million midpoint puts the equity valuation at about 5.9 times projected cash flow, equivalent to a yield near 17%.

Integrated Paytech revenue climbed 20.3% to $23.5 million, faster than CPI's established card businesses, while adjusted EBITDA increased 17.2% to $27.5 million.

You cannot treat that growth as pure profit expansion, however, because operating income in the digital segment declined 12% despite higher sales.

Digital Services Extend the Growth Base

Secure Card Solutions revenue grew 12.9%, and Prepaid Solutions increased 15.1%, showing demand beyond Integrated Paytech. Nine-month free cash flow reached $46.1 million, versus $6.1 million a year earlier. Net leverage improved to 2.6 times adjusted EBITDA from 3.6 times, supporting management's higher annual cash flow outlook.

Debt Makes Cash Flow Quality Essential

CPI held roughly $288 million in debt and finance leases against just $15 million in cash, with senior secured notes carrying 10% interest.

Lower inventory investment helped lift cash flow and may not recur, while digital-segment margins remain under pressure. Your downside cushion depends on repeatable operating cash generation, not merely a favorable working-capital swing.

Are you ready? As revealed in our holiday playbook, Roku Ads Manager lets you easily set up, measure and optimize your self-serve holiday ad campaign. You can even create a shoppable ad unit that lets streamers buy directly from their remote.

Set up your campaign today.

Automotive

Versigent PLC (NYSE: VGNT) reported third-quarter revenue of $2.45 billion, up 7.2%, while adjusted EBITDA increased 10.9% to $275 million. Management raised its annual free cash flow forecast to $275 million to $325 million, lifting the midpoint 20%.

At approximately $42.23 per share, Versigent carried a $2.99 billion market value and a $4.64 billion enterprise value, including net debt.

Against the $990 million midpoint of annual adjusted EBITDA guidance, the business traded at approximately 4.7 times projected operating earnings before interest, taxes, depreciation, and amortization. Expected free cash flow represented roughly 10% of its equity value.

Adjusted sales grew approximately 1% after excluding commodity-price and currency movements, making underlying demand less impressive than reported growth suggests. The $2.1 billion in new bookings gives you additional evidence of customer demand, although those awards do not guarantee immediate revenue.

Higher Margins Strengthen the Operating Case

Versigent supplies electrical systems that carry power, signals, and data through vehicles. Adjusted EBITDA margin increased 40 basis points to 11.2% despite lower global automotive production.

Quarterly operating cash flow reached $225 million, while the higher annual cash forecast creates more room to reduce borrowing if management delivers its projected results.

Borrowing Limits the Valuation Cushion

Versigent carried $2.29 billion in debt against $638 million in cash, with quarterly interest expense of $36 million. Net income fell to $102 million from $109 million, while higher capital spending pushed free cash flow down to $170 million from $179 million.

Stronger margins offer less reassurance when cash generation falls, leaving debt repayment as the clearest test of whether the low valuation deserves your confidence.

Fiserv (NASDAQ: FISV)

Fiserv runs the plumbing behind a huge slice of banking and payments, from your bank’s software to Clover, the card reader at your favorite coffee shop. The stock fell by half last year after a messy reset, and the market has treated it as a cautionary tale ever since. The latest quarter landed right on plan.

Management reaffirmed full-year guidance, doubled its cost-savings target to $1 billion, and lined up a $500 million buyback for the fourth quarter. 

Its banking business returned to growth, even though total revenue is still flat for the year. Fiserv also took a large non-cash goodwill write-down, and cash flow is below last year, but debt keeps falling. That leaves you paying under 10 times this year’s adjusted earnings guidance for a company that moves the money you spend daily.

Novo Nordisk (NYSE: NVO)

Novo makes Ozempic and Wegovy, the drugs that made weight loss a dinner party topic, and its stock has been on a diet of its own as competition and price cuts squeezed the older injectables. The latest quarter showed a healthier patient.

Adjusted operating profit beat expectations, though one-time non-cash write-downs dragged on reported profit, and management raised its full-year outlook for the third time this year. 

The new Wegovy pill is a big seller in eight countries, free cash flow guidance went up, and debt came down. Injectable sales are still slipping, so the pill and new launches need to keep carrying the load.

Even so, you’re paying under 12 times trailing earnings for one of the two biggest names in the hottest corner of medicine, with a dividend on top. A lot of drug for a generic price.

Grifols (NASDAQ: GRFS)

Grifols turns donated blood plasma into medicines for people with immune disorders and other rare conditions, a tightly regulated business with steady demand and only a handful of major global rivals.

For years, the story was all about debt, and the stock traded like the lender was waiting in the lobby. That story keeps getting better. 

Third-quarter revenue grew, profit jumped from a year ago, and sales of its immunoglobulin treatments climbed in the double digits.

Net leverage fell again, free cash flow improved, and the company has already refinanced its 2027 debt, so it has no major maturities until late 2028. Grifols has resumed paying a dividend too. You’re paying 10 times earnings for a plasma leader whose debt is finally moving in the right direction. Watch whether cash generation keeps paying down debt.

Getting the nutrition you deserve doesn’t need to take up all your time. CookUnity delivers fresh dishes handcrafted by award-winning chefs, ready to heat in minutes. Build a custom menu for your entire week, so you can spend your evenings on your terms—not scrubbing pans. Skip, pause, or change your plan size anytime.

Build Your Weekly Menu

That's our coverage for today; thanks for reading! Reply to this email with feedback or any stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge